Literature DB >> 29684341

Predictors of outcome in patients with hematologic malignancies admitted to the intensive care unit.

Nassar Al-Zubaidi1, Emad Shehada1, Khaled Alshabani1, Jihane ZazaDitYafawi1, Pascal Kingah1, Ayman O Soubani2.   

Abstract

PURPOSE: Several studies showed conflicting results about prognosis and predictors of outcome of critically ill patients with hematological malignancies (HM). The aim of this study is to determine the hospital outcome of critically ill patients with HM and the factors predicting the outcome. METHODS AND MATERIALS: All patients with HM admitted to MICU at a tertiary academic medical center were enrolled. Clinical data upon admission and during ICU stay were collected. Hospital, ICU, and 6 months outcomes were documented.
RESULTS: There were 130 HM patients during the study period. Acute Leukemia was the most common malignancy (31.5%) followed by Non-Hodgkin's Lymphoma (28.5%). About 12.5% patients had autologous HSCT and 51.5% had allogeneic HSCT. Sepsis was the most common ICU diagnosis (25.9%). ICU mortality and hospital mortality were 24.8% and 45.3%, respectively. Six months mortality (available on 80% of patients) was 56.7%. Hospital mortality was higher among mechanically ventilated patients (75%). Using multivariate analysis, only mechanical ventilation (OR of 19.0, CI: 3.1-117.4, P: 0.001) and allogeneic HSCT (OR of 10.9, CI: 1.8-66.9, P: 0.01) predicted hospital mortality.
CONCLUSION: Overall hospital outcome of critically ill patients with HM is improving. However those who require mechanical ventilation or underwent allogeneic HSCT continue to have poor outcome.
Copyright © 2018 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29684341     DOI: 10.1016/j.hemonc.2018.03.003

Source DB:  PubMed          Journal:  Hematol Oncol Stem Cell Ther


  9 in total

1.  Outcomes of hospitalized hematologic oncology patients receiving rapid response system activation for acute deterioration.

Authors:  Benjamin Gershkovich; Shannon M Fernando; Brent Herritt; Lana A Castellucci; Bram Rochwerg; Laveena Munshi; Sangeeta Mehta; Andrew J E Seely; Daniel I McIsaac; Alexandre Tran; Peter M Reardon; Peter Tanuseputro; Kwadwo Kyeremanteng
Journal:  Crit Care       Date:  2019-08-27       Impact factor: 9.097

2.  Epidemiology, Clinical Characteristics, and Prognostic Factors in Critically Ill Patients with Hematolymphoid Malignancy.

Authors:  Suhail S Siddiqui; Natesh R Prabu; Harish K Chaudhari; Amit M Narkhede; Satish V Sarode; Ujwal Dhundi; Jigeeshu V Divatia; Atul P Kulkarni
Journal:  Indian J Crit Care Med       Date:  2021-01

3.  Short- and Long-Term Outcomes of Hematologic Malignancy Patients After Cardiopulmonary Resuscitation: Experience of a Large Oncology Center.

Authors:  Mary Lou Warren; Virginia V Schneider; Yun Qing; Lei Feng; Jeanne Y Campbell; Jason W Myers; Marian Von-Maszewski; Cristina Gutierrez
Journal:  J Adv Pract Oncol       Date:  2021-09-01

4.  Acute organ failure and risk of admission to intensive medical care in cancer patients: a single center prospective cohort study.

Authors:  Sara Coelho; Teresa Ribeiro; Isabel Pereira; Delfim Duarte; Ana Afonso; Iolanda Meneses; Sofia Pinelas; Brigitte Pereira; Fernando Coelho; Anabela Martins; Nuno Sousa; Filomena Faria
Journal:  Rev Bras Ter Intensiva       Date:  2022-01-24

5.  Video-Assisted Thoracoscopic Lung Biopsy in Critically Ill Patients With Hematologic Malignancy and Acute Respiratory Distress Syndrome: A Case Series Report.

Authors:  Elizabeth Arrieta; Saveria Sangiovanni; Juan Esteban Garcia-Robledo; Mauricio Velásquez; Luz Fernanda Sua; Liliana Fernández-Trujillo
Journal:  J Investig Med High Impact Case Rep       Date:  2020 Jan-Dec

6.  Outcomes and Risk Factors of Critically Ill Patients with Hematological Malignancy. Prospective Single-Centre Observational Study.

Authors:  Šarūnas Judickas; Raimundas Stasiūnaitis; Andrius Žučenka; Tadas Žvirblis; Mindaugas Šerpytis; Jūratė Šipylaitė
Journal:  Medicina (Kaunas)       Date:  2021-11-30       Impact factor: 2.430

7.  Can treating critically-ill haematological malignancy patients in a separate intensive care unit decrease intensive care unit mortality?

Authors:  Gülbin Aygencel; Nazlıhan Boyacı Dündar; Melda Türkoğlu; Zeynep Arzu Yegin; Zübeyde Nur Özkurt; Abdullah Münci Yağcı
Journal:  Turk J Med Sci       Date:  2021-08-30       Impact factor: 0.973

8.  The use of high-flow nasal oxygen vs. standard oxygen therapy in hematological malignancy patients with acute respiratory failure in hematology wards

Authors:  Nilgün Alptekinoğlu Mendil; Şahin Temel; Recep Civan Yüksel; Kürşat Gündoğan; Bülent Eser; Leylagül Kaynar; Murat Sungur
Journal:  Turk J Med Sci       Date:  2021-08-30       Impact factor: 0.973

9.  Diagnostic performance of Neutrophil CD64 index, procalcitonin, and C-reactive protein for early sepsis in hematological patients.

Authors:  Yu-Xi Shang; Zhi Zheng; Min Wang; Hui-Xia Guo; Yi-Juan Chen; Yue Wu; Xing Li; Qian Li; Jian-Ying Cui; Xiao-Xiao Ren; Li-Ru Wang
Journal:  World J Clin Cases       Date:  2022-03-06       Impact factor: 1.337

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.